AmPath Central Reference Laboratory:

Door No. 1-100/1/CCH Nallagandla, Serilingampally

Hyderabad – 500019
040 6719 9977
www.ampath.com Certificate No.MC-2751
NABL ACCREDITED

PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mrs. Suneeta Soni . Dr. P.Dwivedi SAMPLE TYPE :Bonemarrow aspirate /
JAGRITI PATHOLOGY Peripheral Blood
AGE : 50Y (EDTA/Heparin)
GENDER : Female Lab MR #: 3764093 ORDER REQ. NO :OREQ-AMP-20-1894823
PRIORITY : Routine LAB ORDER. NO :2013071935
OP / IP / DG # : COLLECTED ON :08-Mar-2020 00:00
RECEIVED ON :09-Mar-2020 06:09
REPORT STATUS :Completed

HEMATOLOGY
Test Name (Methodology) Result Flag Units Biological Reference
Interval

Bone Marrow Aspirate Morphological Assessment (Staining and Microscopy)

Flow cytometry No: FC20/306
Bone marrow No: BM20/495

Final Impression: Hemodilute aspirate showing small population of myeloid blasts and hematogones. No
definitive immunophenotypically aberrant population identified.

Clinical details: ?Acute leukemia (pancytopenia).

Specimen: Bone marrow aspirate in EDTA-1, vacutainer, smears-10 unstained labeled.

Bone marrow aspirate examination

Cellularity: Hemodilute.

Megakaryopoiesis:
Cellularity: Not seen.
Morphology: Cannot be commented upon.

BM nucleated cells differential counts – 200 cells counted

Blasts 01 % Monocytes 04 %
Promyelocytes 02 % Eosinophils 00 %
Myelocytes 04 % Basophils 00 %
Metamyelocytes 02 % Lymphocytes 23 %
Band forms 01 % Plasma cells 00 %
Neutrophils 06 % Erythroid precursors 57 %

Erythropoiesis:
Cellularity: Mildly increased.
Morphology: Normoblastic maturation.

Myelopoiesis:
Cellularity: Cannot be commented upon.
Morphology: Normal.
Generated On 10-Mar-2020 17:41:58 1872 This is an electronically authenticated laboratory report. Page 1 of 5

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with
these standards and under the terms and conditions found on the reverse. For details, please email AmPath at customersupport@ampath.com.
 AmPath Central Reference Laboratory:
Door No. 1-100/1/CCH Nallagandla, Serilingampally
Hyderabad – 500019
040 6719 9977
www.ampath.com Certificate No.MC-2751
NABL ACCREDITED

PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mrs. Suneeta Soni . Dr. P.Dwivedi SAMPLE TYPE :Bonemarrow aspirate /
JAGRITI PATHOLOGY Peripheral Blood
AGE : 50Y (EDTA/Heparin)
GENDER : Female Lab MR #: 3764093 ORDER REQ. NO :OREQ-AMP-20-1894823
PRIORITY : Routine LAB ORDER. NO :2013071935
OP / IP / DG # : COLLECTED ON :08-Mar-2020 00:00
RECEIVED ON :09-Mar-2020 06:09
REPORT STATUS :Completed

HEMATOLOGY
Test Name (Methodology) Result Flag Units Biological Reference
Interval

Blasts: Auer rod not seen.

Lymphocytes and plasma cells: Normal in number and morphology.

Flow cytometric immunophenotyping

Specimen: Bone marrow aspirate

Panel: Acute Leukemia

Gating Strategy(ies): CD45 Vs SSC

On flow cytometric immunophenotyping, a small population (2-4% of viable events) of myeloid blasts are seen
(CD34 positive / CD117 positive / CD13 positive / CD33 positive / HLA-DR). In addition a smaller population of
B progenitors (~1% of viable events) with normal maturation pattern is noted, suggestive of hematogones. B and T-
Lymphocytes constitute ~2.5% and ~10% of all viable events.

Final Impression: Hemodilute aspirate showing small population of myeloid blasts and hematogones. No
definitive immunophenotypically aberrant population identified.

Comment: Kindly correlate with clinical details, treatment history and other laboratory parameters.

Generated On 10-Mar-2020 17:41:58 1872 This is an electronically authenticated laboratory report. Page 2 of 5

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with
these standards and under the terms and conditions found on the reverse. For details, please email AmPath at customersupport@ampath.com.
 AmPath Central Reference Laboratory:
Door No. 1-100/1/CCH Nallagandla, Serilingampally
Hyderabad – 500019
040 6719 9977
www.ampath.com Certificate No.MC-2751
NABL ACCREDITED

PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mrs. Suneeta Soni . Dr. P.Dwivedi SAMPLE TYPE :Bone marrow biopsy in FMA
JAGRITI PATHOLOGY ORDER REQ. NO :OREQ-AMP-20-1894823
AGE : 50Y LAB ORDER. NO :2013071935
GENDER : Female Lab MR #: 3764093 COLLECTED ON :08-Mar-2020 00:00
PRIORITY : Routine RECEIVED ON :09-Mar-2020 06:09
OP / IP / DG # : REPORT STATUS :Completed

HEMATOLOGY
Test Name (Methodology) Result Flag Units Biological Reference
Interval

Bone Marrow Biopsy Bone marrow No:

BM20/495
Observations:
Flow cytometry No: FC20/306
Bone marrow No: BM20/495

Final Impression: Hypercellular bone marrow shows megaloblastoid erythroid hyperplasia. See notes.

Clinical details: ?Acute leukemia (pancytopenia).

Specimen: Bone marrow biopsy in labeled container.

Bone marrow biopsy examination

Gross: Received a single linear bony tissue bit measuring 3.2 cm in length, submitted entirely for processing
(BM-20/495).

Microscopic examination:
Biopsy consists of cortical bone, normal bony trabeculae and intertrabecular spaces showing hypercellular bone
marrow (cellularity ~90 %).
Megakaryocytes are adequate in numbers and with dyspoiesis in ~20%, in the form of fragmented nuclei.
Moderate erythroid hyperplasia with normal to megaloblastic maturation is noted.
Myelopoiesis is adequate and shows normal maturation pattern.
Lymphocytes and plasma cells are seen in the background.
Few singly scattered blasts are seen.

Final Impression: Hypercellular bone marrow shows megaloblastoid erythroid hyperplasia. See notes.

Comment: Kindly correlate with clinical details, treatment history and other laboratory parameters, including
Vit12 and folate levels.

Notes: Possibilities considered are – 1) Megaloblastic anemia, 2) Myelodysplastic syndrome without excess of
blasts, 3) Partially treated acute leukemia.

Generated On 10-Mar-2020 17:41:58 1872 This is an electronically authenticated laboratory report. Page 3 of 5

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with
these standards and under the terms and conditions found on the reverse. For details, please email AmPath at customersupport@ampath.com.
 AmPath Central Reference Laboratory:
Door No. 1-100/1/CCH Nallagandla, Serilingampally
Hyderabad – 500019
040 6719 9977
www.ampath.com Certificate No.MC-2751
NABL ACCREDITED

PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mrs. Suneeta Soni . Dr. P.Dwivedi SAMPLE TYPE :BMA/PB-(EDTA/Heparin)/
JAGRITI PATHOLOGY Smears
AGE : 50Y ORDER REQ. NO :OREQ-AMP-20-1894823
GENDER : Female Lab MR #: 3764093 LAB ORDER. NO :2013071935
PRIORITY : Routine COLLECTED ON :08-Mar-2020 00:00
OP / IP / DG # : RECEIVED ON :09-Mar-2020 06:09
REPORT STATUS :Completed

HEMATOLOGY
Test Name (Methodology) Result Flag Units Biological Reference
Interval

Flowcytometry Panel - Acute Leukemia Comprehensive Characterization (Flow Cytometry)

Flow cytometry No: FC20/306
Bone marrow No: BM20/495

Final Impression: Hemodilute aspirate showing small population of myeloid blasts and hematogones. No
definitive immunophenotypically aberrant population identified.

Clinical details: ?Acute leukemia (pancytopenia).

Specimen: Bone marrow aspirate in EDTA-1, vacutainer, smears-10 unstained labeled.

Bone marrow aspirate examination

Cellularity: Hemodilute.

Megakaryopoiesis:
Cellularity: Not seen.
Morphology: Cannot be commented upon.

BM nucleated cells differential counts – 200 cells counted

Blasts 01 % Monocytes 04 %
Promyelocytes 02 % Eosinophils 00 %
Myelocytes 04 % Basophils 00 %
Metamyelocytes 02 % Lymphocytes 23 %
Band forms 01 % Plasma cells 00 %
Neutrophils 06 % Erythroid precursors 57 %

Erythropoiesis:
Cellularity: Mildly increased.
Morphology: Normoblastic maturation.

Myelopoiesis:
Cellularity: Cannot be commented upon.
Morphology: Normal.

Generated On 10-Mar-2020 17:41:58 1872 This is an electronically authenticated laboratory report. Page 4 of 5

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with
these standards and under the terms and conditions found on the reverse. For details, please email AmPath at customersupport@ampath.com.
 AmPath Central Reference Laboratory:
Door No. 1-100/1/CCH Nallagandla, Serilingampally
Hyderabad – 500019
040 6719 9977
www.ampath.com Certificate No.MC-2751
NABL ACCREDITED

PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mrs. Suneeta Soni . Dr. P.Dwivedi SAMPLE TYPE :BMA/PB-(EDTA/Heparin)/
JAGRITI PATHOLOGY Smears
AGE : 50Y ORDER REQ. NO :OREQ-AMP-20-1894823
GENDER : Female Lab MR #: 3764093 LAB ORDER. NO :2013071935
PRIORITY : Routine COLLECTED ON :08-Mar-2020 00:00
OP / IP / DG # : RECEIVED ON :09-Mar-2020 06:09
REPORT STATUS :Completed

HEMATOLOGY
Test Name (Methodology) Result Flag Units Biological Reference
Interval

Blasts: Auer rod not seen.

Lymphocytes and plasma cells: Normal in number and morphology.

Flow cytometric immunophenotyping

Specimen: Bone marrow aspirate

Panel: Acute Leukemia

Gating Strategy(ies): CD45 Vs SSC

On flow cytometric immunophenotyping, a small population (2-4% of viable events) of myeloid blasts are seen
(CD34 positive / CD117 positive / CD13 positive / CD33 positive / HLA-DR). In addition a smaller population of
B progenitors (~1% of viable events) with normal maturation pattern is noted, suggestive of hematogones. B and T-
Lymphocytes constitute ~2.5% and ~10% of all viable events.

Final Impression: Hemodilute aspirate showing small population of myeloid blasts and hematogones. No
definitive immunophenotypically aberrant population identified.

Comment: Kindly correlate with clinical details, treatment history and other laboratory parameters.

Authorized by Dr. Prashant Ajit Deshpande MD (TMH), Postdoctoral Fellow (Hematopathology and
Checked by Mr. Srinivas Molecular Hematology)
Kurapati Consultant - Hematopathology and Molecular Pathology
Associate 10-Mar-2020 17:41
-----End of Report-----
Tests marked with (*) are not included in the scope of NABL accreditation

Generated On 10-Mar-2020 17:41:58 1872 This is an electronically authenticated laboratory report. Page 5 of 5

AmPath upholds rigorous standards for operational and clinical performance based on US hospital benchmarks. Test results have been furnished in adherence with
these standards and under the terms and conditions found on the reverse. For details, please email AmPath at customersupport@ampath.com.